Astellas extends offer period for OSI shares
This article was originally published in Scrip
Executive Summary
Astellas has extended its tender offer for OSI Pharmaceuticals to midnight New York City time on 2 June, giving a few more weeks for investors to offer their shares. The already extended all-cash tender was originally set to expire on 17 May. The Japanese firm yesterday announced a definitive agreement to acquire OSI for around $4 billion, after it raised its offer price from $52.00 to $57.50 per share (scripnews.com, 17 May 2010).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.